Lilly's Once-Weekly Insulin Top-Line Results Show Benefit :

Phase 3 data for efsitora alfa showed noninferiority to once-daily basal insulins in two studies of people with type 2 diabetes.

Related Keywords

Los Angeles , Eli Lilly , Annel Peters , European Association For The Study Of Diabetes , Drug Administration Endocrinologic , Novo Nordisk , University Of Southern California Westside Center , Metabolic Drugs Advisory Committee , Drug Administration , Metabolic Drugs Advisory , Affordability Are , Southern California Westside Center , Medscape Medical News , Data Show Noninferiority , Daily Basal , European Association ,